Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
Optimi Health completed and quality-released a production batch of 5mg naturally derived psilocybin capsules manufactured at its cGMP facility in Princeton, British Columbia. The same batch will supply a Health Canada-authorized Phase 2 open-label trial of psilocybin-assisted therapy in major depressive disorder (up to 200 participants, dosing expected complete by end of 2027) and ongoing commercial supply to licensed Australian clinics treating treatment-resistant depression.
Key figures
- Drug Name
- psilocybin 5mg capsules (naturally derived)
- Phase Of Trial
- Phase 2
- Dosing completion
- end of 2027
- Clinicians trained
- more than 750
- Trial participants
- up to 200
- Commercial supply since
- 2025
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.